Table 3.

Cost-effectiveness, Sensitivity Analysis

Strategy	Mean Costs, $	Mean Effects, QALMs	Incremental Costs, $	Incremental Effects, QALMs	ICER†, $/QALM gained
Cure rate of community pharmacist-initiated antibiotic-treatment (86%)
Community pharmacist-initiated	72.81 (49.77; 99.77)	0.75229 (0.51536; 0.92437)	–	–	–
Family physician-initiated	142.01 (95.73; 197.40)	0.75233 (0.51488; 0.92407)	69.20 (15.50; 129.40)	0.00004 (−0.00726; 0.00698)	1,730,000
Emergency physician-initiated	371.09 (232.14; 546.54)	0.75237 (0.51973; 0.92503)	–	–	Extended dominance
Cure rate of community pharmacist-initiated antibiotic-treatment (83%)
Community pharmacist-initiated	72.90 (50.07; 100.88)	0.75326 (0.52212; 0.92515)	–	–	–
Family physician-initiated	141.74 (94.71; 197.46)	0.75328 (0.52284; 0.92450)	68.85 (14.61; 129.57)	0.00002 (−0.00714; 0.00701)	3,442,500
Emergency physician-initiated	370.36 (229.47; 546.86)	0.75333 (0.52349; 0.92436)	–	–	Extended dominance

^†Sequential analysis